SCHOTT Pharma AG & Co. KGaA (IT:1SXP)

:1SXP

1SXP

SCHOTT Pharma AG & Co. KGaA

RESEARCH TOOLSreports

Want to see IT:1SXP full AI Analyst Report?

SCHOTT Pharma AG & Co. KGaA (1SXP) Stock Forecast & Price Target

3 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

1SXP Analyst Ratings

Moderate Buy

2 Buy

4 Hold

0 Sell

Based on 6 analysts giving stock ratings to

SCHOTT

Pharma AG & Co. KGaA

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

1SXP Stock 12 Month Forecast

Average Price Target

€18.87

▼(-5.38% Downside)

Based on 6 Wall Street analysts offering 12 month price targets for SCHOTT Pharma AG & Co. KGaA in the last 3 months. The average price target is €18.87 with a high forecast of €25.70 and a low forecast of €15.50. The average price target represents a -5.38% change from the last price of €19.94.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"12":"€12","21":"€21","30":"€30","16.5":"€16.5","25.5":"€25.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€25.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.866666666666667,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€18.87</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€15.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[12,16.5,21,25.5,30],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.5,14.438461538461539,15.376923076923077,16.315384615384616,17.253846153846155,18.192307692307693,19.130769230769232,20.06923076923077,21.00769230769231,21.946153846153848,22.884615384615387,23.823076923076925,24.76153846153846,{"y":25.7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.5,13.912820512820513,14.325641025641026,14.73846153846154,15.15128205128205,15.564102564102564,15.976923076923077,16.38974358974359,16.8025641025641,17.215384615384615,17.628205128205128,18.04102564102564,18.453846153846154,{"y":18.866666666666667,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.5,13.653846153846153,13.807692307692308,13.961538461538462,14.115384615384615,14.26923076923077,14.423076923076923,14.576923076923077,14.73076923076923,14.884615384615385,15.038461538461538,15.192307692307693,15.346153846153847,{"y":15.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":29.332,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":29.332,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.147,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.554,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.455,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.715,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.283,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.278,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.962,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.624,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.379,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.36,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.5,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€25.70

Average Price Target€18.87

Lowest Price Target€15.50

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Jonathon Unwin

Barclays

€15→€16

Hold

-19.76%

Downside

Reiterated

04/28/26

Barclays Sticks to Its Hold Rating for SCHOTT Pharma AG & Co. KGaA (1SXP)

Falko Friedrichs

Deutsche Bank

€16

Hold

-19.76%

Downside

Reiterated

03/30/26

SCHOTT Pharma AG & Co. KGaA (1SXP) Gets a Hold from Deutsche Bank

Charles Weston

RBC Capital

€18

Hold

-9.73%

Downside

Reiterated

02/19/26

RBC Capital Remains a Hold on SCHOTT Pharma AG & Co. KGaA (1SXP)

Christian Ehmann

Berenberg Bank

€22

Buy

10.33%

Upside

Reiterated

02/12/26

Berenberg Bank Keeps Their Buy Rating on SCHOTT Pharma AG & Co. KGaA (1SXP)

Olivier Calvet

UBS

€25.7

Buy

28.89%

Upside

Reiterated

02/11/26

UBS Reaffirms Their Buy Rating on SCHOTT Pharma AG & Co. KGaA (1SXP)

James Vane

Jefferies

€15.5

Hold

-22.27%

Downside

Reiterated

02/11/26

Jefferies Reaffirms Their Hold Rating on SCHOTT Pharma AG & Co. KGaA (1SXP)

Unknown Analyst

DZ BANK AG

Not Ranked

DZ BANK AG

―

Buy

―

Reiterated

12/05/25

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Jonathon Unwin

Barclays

€15→€16

Hold

-19.76%

Downside

Reiterated

04/28/26

Barclays Sticks to Its Hold Rating for SCHOTT Pharma AG & Co. KGaA (1SXP)

Falko Friedrichs

Deutsche Bank

€16

Hold

-19.76%

Downside

Reiterated

03/30/26

SCHOTT Pharma AG & Co. KGaA (1SXP) Gets a Hold from Deutsche Bank

Charles Weston

RBC Capital

€18

Hold

-9.73%

Downside

Reiterated

02/19/26

RBC Capital Remains a Hold on SCHOTT Pharma AG & Co. KGaA (1SXP)

Christian Ehmann

Berenberg Bank

€22

Buy

10.33%

Upside

Reiterated

02/12/26

Berenberg Bank Keeps Their Buy Rating on SCHOTT Pharma AG & Co. KGaA (1SXP)

Olivier Calvet

UBS

€25.7

Buy

28.89%

Upside

Reiterated

02/11/26

UBS Reaffirms Their Buy Rating on SCHOTT Pharma AG & Co. KGaA (1SXP)

James Vane

Jefferies

€15.5

Hold

-22.27%

Downside

Reiterated

02/11/26

Jefferies Reaffirms Their Hold Rating on SCHOTT Pharma AG & Co. KGaA (1SXP)

Unknown Analyst

DZ BANK AG

Not Ranked

DZ BANK AG

―

Buy

―

Reiterated

12/05/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering SCHOTT Pharma AG & Co. KGaA

3 Months

xxx

Success Rate

0/4 ratings generated profit

Average Return

-7.07%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 0.00% of your transactions generating a profit, with an average return of -7.07% per trade.

1 Year

Christian EhmannBerenberg Bank

Success Rate

0/4 ratings generated profit

Average Return

-5.92%

Copying Christian Ehmann's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -5.92% per trade.

2 Years

xxx

Success Rate

0/4 ratings generated profit

Average Return

-5.92%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -5.92% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1SXP Analyst Recommendation Trends

Rating

Dec 25

Jan 26

Feb 26

Mar 26

Apr 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 1SXP has received 2 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. 1SXP average Analyst price target in the past 3 months is 18.87.

Each month's total comprises the sum of three months' worth of ratings.

1SXP Financial Forecast

1SXP Earnings Forecast

The previous quarter’s earnings for 1SXP were €0.22.

1SXP Sales Forecast

The previous quarter’s earnings for 1SXP were €240.19M.

1SXP Stock Forecast FAQ

What is IT:1SXP’s average 12-month price target, according to analysts?

Based on analyst ratings, SCHOTT Pharma AG & Co. KGaA’s 12-month average price target is 18.87.

What is IT:1SXP’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for IT:1SXP, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is SCHOTT Pharma AG & Co. KGaA a Buy, Sell or Hold?

SCHOTT Pharma AG & Co. KGaA has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 4 hold ratings and 0 sell ratings.

What is SCHOTT Pharma AG & Co. KGaA’s share price target?

The average share price target for SCHOTT Pharma AG & Co. KGaA is 18.87. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €25.70 ,and the lowest forecast is €15.50. The average share price target represents -5.38% Decrease from the current price of €19.94.

What do analysts say about SCHOTT Pharma AG & Co. KGaA?

SCHOTT Pharma AG & Co. KGaA’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of SCHOTT Pharma AG & Co. KGaA?

To buy shares of IT:1SXP, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

SCHOTT Pharma AG & Co. KGaA (1SXP) Stock Forecast & Price Target

1SXP Analyst Ratings

1SXP Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering SCHOTT Pharma AG & Co. KGaA

1SXP Analyst Recommendation Trends

1SXP Financial Forecast

1SXP Earnings Forecast

1SXP Sales Forecast

1SXP Stock Forecast FAQ

Detailed List of Analyst Forecasts